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Background: Thrombopoietin receptor agonists have been repeatedly confirmed to be safe, efficient, and well tolerated in pediat-
ric patients with chronic immune thrombocytopenia (cITP). Material and methods: In this report, we present data summarizing the 
Polish experience of the use of eltrombopag in cITP patients, refractory to standard first-line care. Our analysis was based on clinical 
and epidemiological data from the Nationwide Therapeutic Program 2018–2020. Quality of the response to the eltrombopag treat-
ment was defined according to the International Consensus Guidelines as follows: complete response (CR) defined as platelet count 
(PLT) ≥100 x 109/L and absence of bleeding; response (R) defined as PLT ≥30 x 109/L and at least two-fold increase in the baseline count 
and absence of bleeding. Results: We evaluated 60 patients (33 boys and 27 girls) with chronic and refractory ITP. Median age at begin-
ning of treatment was 9.5 years. Median PLT at the first eltrombopag administration was 30 x 109/L. The median follow-up was 7 months 
(range, 3–22 months). After 1 week of treatment, response (R) was noted in 53.3% (95% confidence interval [CI]: 40.7%–66.0%) patients, 
and complete response (CR) was seen in 21.6% (95% CI: 11.2%–32.1%). We evaluated the long-term duration of the response and found 
that it was obtained in 84.4% (95% CI: 71.8%–97.0%) and 88.9% (95% CI: 77.0%–100%) of patients after 6 and 12 months, respectively, of 
eltrombopag therapy, while CR was reached, respectively, in 46.9% (95% CI: 29.6%–64.2%) and 29.6% (95% CI: 12.4%–46.9%) patients. 
No serious adverse events were reported. Conclusion: Our data support the safety and efficacy of eltrombopag use in cITP pediatric 
patients.
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Introduction
Primary immune thrombocytopenia (ITP) is one of the most common 
hematological disorders in childhood. It is usually a mild, self-limiting 
disease, without life-threatening bleeding episodes or the need for 
hospitalization [1, 2]. About 20%–30% of children develop chronic ITP 
(cITP), defined as thrombocytopenia persisting longer than 12 months 
[3, 4]. In some situations, treatment of cITP cases is more complex 
than the use of first-line treatment with steroid cycles or intravenous 
immunoglobulins (IVIGs). If immunosuppressive therapy fails, 
other drug groups should be considered. Thrombopoietin receptor 
agonists (TPO-RAs) stimulate the proliferation and maturation of 
megakaryocytes due to their interactions with the thrombopoietin 
receptor, resulting in platelet count increase [4]. It has been proven 
that TPO-RAs are one of the highly effective alternative treatment 
options before and after splenectomy and other agents in the adult 
population [5, 6]. Several studies have confirmed the safety, efficacy, 
and good tolerance of TPO-RAs in pediatric patients, especially orally 
administered eltrombopag [7, 8]. Based on these results, since 2018, 
in Poland, the National Therapeutic Program (NTP) for chronic ITP, as 
announced by the Ministry of Health and reimbursed by the National 
Health Fund (NFZ), has allowed the use of eltrombopag in ITP patients 
refractory to standard first-line care.
In this report, we present the data summarizing the first 2 years’ 
experience of the NTP with eltrombobag in pediatric cITP.
Material and methods
Retrospective analysis of epidemiological and clinical data of pediatric 
cITP patients was conducted after the first 2-year period of introduction 
of the NTP. Demographic and baseline ITP data and treatment-related 
data were obtained from the central monitoring electronic system 
created for the NTP. The monitoring data base was founded by the 
NFZ and consulted by  the first author of this report as an assigned 
coordinator. According to the NTP enrollment criteria, all patients were 
diagnosed with cITP, defined as a platelet count (PLT) <100 x 109/L for 
a period of at least 12 months or longer, who were resistant to previous ITP 
treatment (IVIGs and steroids) and were in the age range of 1–18 years.
After enrollment into the NTP group and final qualification for the 
eltrombopag treatment, the diagnostic tests were scheduled for each 
patient as follows: full blood count every week during the first month 
of treatment and every month later on; biochemistry tests of the liver 
function enzymes every 2 weeks in the first month and every 3 months 
in the following phase of treatment (elevated transaminases were 
defined as 3-fold increase of normal value); and ophthalmological 
examination every 6 months.
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Quality of the response to the eltrombopag treatment was defined 
according to the International Consensus Guidelines as follows: 
complete response (CR) was defined as PLT ≥100 x 109/L and absence 
of bleeding; response (R) was defined as PLT ≥30 x 109/L and at least 
two-fold increase in the baseline count and absence of bleeding; no 
response (NR) as PLT ≤30 x 109/L or <2-fold increase of baseline 
platelet count or bleeding; and duration of response was measured 
from the achievement of CR or R to the time of loss of CR or R [3].
Statistical analysis
Descriptive analysis was performed, with median and range values. 
Response and complete response rates at each time point were 
provided with 95% confidence intervals (95% CIs) [9].
Results
The total number of 62 children was qualified to receive the 
therapeutic program of therapy with eltrombopag for cITP between 
March 2018 and March 2020. Two patients did not meet the criteria 
of cITP and were excluded from this analysis. Among all patients 
treated with eltrombopag, 33 were boys and 27 girls (Tab. I). 
The median age at the date of NTP enrollment was 9.5 years 
(2–17 years). At the beginning of treatment, the median PLT was 
30 x 109/L (range: 1–98 x 109/L). The median follow-up was 7 months 
(range: 3–22 months).
After the first week of eltrombopag therapy, the median PLT was 
51 x 109/L, CR was observed in 21.6% (95% CI: 11.2%–32.1%) 
patients, and R was achieved in 53.3% (95% CI: 40.7%–66.0%) 
of patients. After the first 4 weeks of therapy, CR was observed in 
33.3% (95% CI: 20.4%–46.3%), and R was noted in 72.6% (95% 
CI: 60.3%–84.8%) patients. Additionally, eltrombopag efficacy and 
response duration was evaluated in patients with complete laboratory 
and clinical data at the time points of 6 months and 12 months after 
beginning of therapy. The long-term duration of the response was 
assessed, and we found that it was obtained in 84.4% (95% CI: 
71.8%–97.0%) and in 88.9% (95% CI: 77.0%–100%) of patients 
after6 and 12 months, respectively, of eltrombopag therapy, while 
CR was reached, respectively, in 46.9% (95% CI: 29.6%–64.2%) and 
29.6% (95% CI: 12.4%–46.9%) patients (Fig. 1).
No serious adverse effects were observed. In only one patient 
a transient increase in transaminases level was reported.
Discussion
Data on eltrombopag use in children with cITP are limited and 
are mostly based on evidence from studies in adults, few clinical 
randomized trials, or single-center experiences. This observational 
report is a retrospective evaluation of the first 2 years of Polish 
experience with eltrombopag use in clinical practice in pediatric 
patients. So far, eltrombopag is the only available option of TPO-RA 
reimbursed by the National Health Fund for cITP pediatric patients 
in Poland. This determines the final results and also limits the final 
choice of second-line therapy for children and adults with cITP, 
refractory to previous steroid or IVIGs treatment.
In all 60 patients, eltrombopag therapy was well tolerated 
and safe during the observational period of almost 2 years, 
consistent with the results of prior publications [10]. The overall 
3-month, 6-month, and 12-month response rate to eltrombopag in 
this demonstrated group was over 80%, which is also comparable 
to the results from previous pediatric international studies [11–14]. 
Response duration and response quality were satisfactory, and 
moreover, constantly rising in time. Almost 90% of the followed-up 
and evaluated patients presented durable response with sustained 
platelet response (≥30 x 109/L). Indirectly, we can assume that this 
helped not only to improve the platelet count in every single patient 
but also decreased the need for other ITP therapies and resulted 
in improvement of quality of life (QoL). Nevertheless, no data are 
available whether eltrombopag therapy reduced the percentage of 
patients who required other concomitant drugs or salvage therapies.
Recently, the American Society of Hematology (ASH) published 
updated recommendations for adult and pediatric patients with ITP, 
including cITP [1]. The panel of experts agreed on several new 
diagnostic and management approaches, including the use of TPO-
RAs. Regarding the disease-related definitions and the diagnostic 
routine, these have not been changed since 2011 [15]; current 
treatment recommendations favor therapies that avoid the side 
effects of medication and have minimal negative impact on health-
related QoL (HRQoL) (Tab. II).
Table I. Data of pediatric patients treated with eltrombopag in 
NTP in Poland 2018–2020
Characteristics Value 
Gender
 Male, No (%)
 Female, No (%)
33 (55)
27 (45)
Age at start of eltrombopag treatment, years
 Median (range) 9.5 (2–17)
Baseline PLT count, 109/L
 Median (range)
Median starting dose, mg
 Median (range)
Eltrombopag efficacy in time
 TW1
   Median PLT count, 109/L; median (range)
   Patients with R; No./TOT (%)
   Patients with CR; No./TOT (%)
 T1
   Median PLT count, 109/L; median (range)
   Patients with R; No./TOT (%)
   Patients with CR; No./TOT (%)
 T3
   Median PLT count, 109/L; median (range)
   Patients with R; No./TOT (%)
   Patients with CR; No./TOT (%)
 T6
   Median PLT count, 109/L; median (range)
   Patients with R; No./TOT (%)
   Patients with CR; No./TOT (%)
 T12
   Median PLT count, 109/L; median (range)
   Patients with R; No./TOT (%)


















NTP – National Therapeutic Program; No – number; M – male; F – female; PLT – platelet 
count; TW – after 1 week; T1 – after 1 month; T3 – after 3 months; T6 – after 6 months; 
T12 – after 12 months; CR – complete remission; R – remission; TOT – total number
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In children with newly diagnosed ITP (ndITP) who have no or mild 
bleeding only, regardless of the platelet count, the ASH guideline 
panel suggests outpatient treatment rather than hospital admission. 
Similarly, observation is preferred rather than steroid, IVIGs, or 
anti-D therapy in ndITP children with no bleeding or skin bleeding 
manifestation only. In children with ndITP with no life-threatening 
bleeding or no diminished HRQoL, the ASH panel suggest steroids 
as the first-line ITP therapy preferably over IVIGs or anti-D. In children 
who do not have response to first-line treatment, it is recommended to 
use TPO-RAs rather than rituximab or splenectomy. The expert panel 
recognized the use of TPO-RAs as being beneficial with reference 
to durable response and reduction or discontinuation of steroid use.
Conclusion
These initial data of the Polish Therapeutic Program support the 
safety and efficacy of eltrombopag use in chronic ITP pediatric 
patients, with almost 90% response in 12-month follow-up.
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CR – complete response; R – response; TW1 – after 1 week; T1 – after 1 month; T3 – after 3 months; T6 – after 
6 months; T12 – after 12 months; lines of trends are shown 
TW1 T1 T3 T6 T12  [TIME POINTS]
R
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Fig. 1. Time-dependent respon e to el romb pag therapy
CR – complete response; R – response; TW1 – after 1 week; T1 – after 1 month; T3 – after 3 months; T6 –  after 6 months; T12 – after 12 months; lines of trends are shown
Table II. ASH recommendations for therapy in children with chronic ITP [1]
Management approach Recommendation
Observation In children with ndITP who have no or mild bleeding only (skin manifestation), regardless of the platelet count
In children with ndITP who have no or minor bleeding preferred over corticosteroids, anti-D, or IVIGs
First-line therapy In children with ndITP who have non–life-threatening mucosal bleeding and/or diminished HRQoL, corticosteroid courses rather 
than anti-D or IVIGs
- Steroid courses not longer than 7 days
- Prednisone preferably
- Dosing:
(i) Prednisone 2-4 mg/kg/day; maximum 120 mg daily; for 5–7 days
(ii) Dexamethasone 0.6 mg/kg/day; maximum 40 mg/kg/day, for 4 days
Anti-D or IVIGs comparatively
Second-line therapy In children with ITP who have non–life-threatening mucosal bleeding and/or diminished HRQoL and do not respond to first-line 
treatment:
- TPO-RAs rather than rituximab
- TPO-RAs rather than splenectomy
- rituximab rather than splenectomy
ITP – immune thrombocytopenia; ndITP – newly diagnosed ITP; HRQoL – health-related quality of life; IVIGs – intravenous immunoglobulins; TPO-Ras – thrombopoietin receptor agonists
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